Rigel Pharmaceuticals, Inc.
RIGLNASDAQHealthcare● Active
$30.26
+$0.33(+1.12%)
Market Cap$559943249
P/E Ratio—
52W High$52.24
52W Low$18.14
Rigel Pharmaceuticals, Inc. (RIGL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RIGL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.29B | $0.18B | $0.12B | $0.12B | $0.15B |
| Cost of Revenue | $0.02B | $0.02B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.27B | $0.16B | $0.11B | $0.12B | $0.15B |
| Gross Margin %(computed) | 93.33% | 89.60% | 93.92% | 98.55% | 99.27% |
| Operating Expenses | |||||
| R&D Expenses | $0.03B | $0.02B | $0.02B | $0.06B | $0.07B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.15B | $0.14B | $0.13B | $0.17B | $0.16B |
| Operating Income | $0.13B | $0.02B | ($0.02B) | ($0.06B) | ($0.01B) |
| Operating Margin %(computed) | 42.63% | 13.49% | -17.53% | -46.20% | -8.37% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Income Before Tax | $0.12B | $0.02B | ($0.03B) | ($0.06B) | ($0.02B) |
| Income Tax Expense | ($0.25B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | $0.37B | $0.02B | ($0.03B) | ($0.06B) | ($0.02B) |
| Net Margin %(computed) | 124.72% | 9.75% | -21.47% | -48.71% | -12.00% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $20.40 | $0.99 | $-1.44 | $-3.40 | $-1.10 |
| Wtd Avg Shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| EBITDA | $0.13B | $0.03B | ($0.02B) | ($0.05B) | ($0.01B) |
| EBITDA Margin %(computed) | 44.71% | 15.90% | -14.53% | -44.80% | -7.56% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Rigel Pharmaceuticals, Inc. data
About Rigel Pharmaceuticals, Inc. (RIGL) Income Statement
Rigel Pharmaceuticals, Inc. (RIGL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RIGL reported revenue of $0.29B, gross profit of $0.27B (gross margin 93.33%), and net income of $0.37B — a net profit margin of 124.72%.
Frequently asked questions
RIGL · 4 questionsRigel Pharmaceuticals, Inc. (RIGL) reported revenue of $0.29B for 2025, up 64.1% year-over-year.
RIGL revenueRIGL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08